Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood

Inclusion Criteria:

* BMI between 25 and 42 kg/m2
* Diet-controlled diabetics, or diabetics on Metformin that have permission from Primacy Care Physician to wash-out of the drug for 6 weeks prior to the study and for the duration of the study
* HbA1C between 6.0 - 7.9 (those on Metformin must have a HbA1c level below 7.5 prior to wash-out period)
* Fasting Blood Glucose \< 150 mg/dl
* Women must be post-menopausal or surgically sterile within age range
* Subjects must live in vicinity of Stanford University

Exclusion Criteria:

* Prior Bariatric surgery
* Personal or family history of medullary thyroid cancer
* MEN2 Syndrome
* Thyroid Nodules (not evaluated by PCP)
* Pancreatitis (acute or chronic)
* Gallstones
* Fasting plasma triglycerides \> 400 mg/dl
* Cardiovascular disease
* Major organ disease
* Unstable hypertension (BP \>160/100 mm Hg)
* Heavy alcohol use
* Self-reported weight change of \>2kg over past 6 weeks
* Medication known to affect blood glucose, insulin sensitivity, or inflammation
* NSAIDs (must cease use 4 weeks prior to study enrollment)
* Previous use of liraglutide, Januvia, Byetta, or Lira.